GI-181771X is part of a class of organic compounds known as benzodiazepines. It is a cholecystokinin 1 receptor agonist investigated by GlaxoSmithKline for the treatment of obesity. In one study, GI181771X did not reduce body weight and had no effect on waist circumference or other cardiometabolic risk markers. This negative result was later assigned to an inadequate trial design rather than compound activity. Gastrointestinal side effects were more common with GI181771X than with placebo treatment. Also, in rodents, morphological changes in the pancreas were observed after administration of GI-181771X, including necrotizing pancreatitis, acinar cell hypertrophy/atrophy, zymogen degranulation, focal acinar cell hyperplasia, and interstitial inflammation. In contrast however, pancreatic changes were not observed in monkeys or in human obese patients (in a clinical trial).